Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
0(0%)
Results Posted
50%(3 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_2
3
38%
Ph phase_1
3
38%
Ph phase_3
2
25%

Phase Distribution

3

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
3(37.5%)
Phase 2Efficacy & side effects
3(37.5%)
Phase 3Large-scale testing
2(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(6)
Terminated(2)

Detailed Status

Completed6
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (37.5%)
Phase 23 (37.5%)
Phase 32 (25.0%)

Trials by Status

terminated225%
completed675%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_1

Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment

NCT01594957
completedphase_1

Pharmacokinetics of LCQ908 in Patients With Renal Impairment

NCT01558323
completedphase_1

Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia

NCT01146522
completedphase_2

A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia

NCT01594983
terminatedphase_3

Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.

NCT01589237
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT01594957Phase 1

Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment

Completed
NCT01558323Phase 1

Pharmacokinetics of LCQ908 in Patients With Renal Impairment

Completed
NCT01146522Phase 1

Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia

Completed
NCT01594983Phase 2

A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia

Completed
NCT01589237Phase 3

Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.

Terminated
NCT01811472Phase 2

Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients

Completed
NCT01514461Phase 3

A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome

Completed
NCT01387958Phase 2

A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients

Terminated

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8